Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
批准号:
9925059
负责人:
GENHONG CHENG
金额:
$75.04万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-02 至 2023-04-30
关键词:
AddressAffectAfricanAge-MonthsAmericanAmericasAnatomyAnti-Inflammatory AgentsAntibodiesAsiansBiteBloodCD14 geneCell physiologyCellsClinicalCollaborationsComplexCulicidaeDNA Sequence AlterationDataDefectDevelopmentDiseaseDisease OutbreaksEpidemicEvolutionExposure toGeneticGenomicsGenotypeGeographyHumanImmuneImmune responseImmune systemImmunityImmunoglobulin MImmunologicsImmunosuppressionInfantInfectionInflammationJointsLeadLifeMaternal-Fetal TransmissionMeasuresMediatingMethodsMicrocephalyMolecularMothersMutationOutcomePathogenesisPathogenicityPatientsPatternPerinatalPeripheralPlacentaPoint MutationPopulationPregnancyPregnancy OutcomePregnant WomenProspective cohortPublishingRNA SequencesRecurrenceRelapseReportingResearch PersonnelRubellaSeverity of illnessSpecimenStructural Congenital AnomaliesSyndromeTestingThailandTimeUrineVertical Disease TransmissionViralViral GenomeViral Load resultViral PathogenesisViremiaVirusVirus SheddingZIKV infectionZika Virusadverse outcomeadverse pregnancy outcomeantenatalbasecohortcongenital infectioncytokinefetalfollow-upgenetic evolutiongenomic RNAin uteroin vivoinfant outcomemacrophagemonocytemouse modelneonatal infectionneurodevelopmentneutralizing antibodypregnantprospectiveresponsetranslational studytransmission processvirologyvirus genetics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract/Summary
Our group of investigators has been collaborating over the last two years to describe the clinical aspects and
pathogenesis of in utero transmission of ZIKA virus (ZIKV) infection. We have embarked in a strong
collaborative effort to document and understand the pathogenesis of ZIKV. We have available to us a unique
prospective cohort of well characterized ZIKV-infected mother-infant pairs who have been followed since the
antenatal period, with infants now between 12 to 24 months of age and specimens collected over time. We
propose to characterize ZIKV humoral immune responses over time in our cohort of mother-infant pairs who
became infected during the Rio de Janeiro 2015/16 epidemic, in order to determine the timing of development
of immune responses to ZIKV in perinatally infected infants, and possible correlation with intermittent viral
shedding. We plan to evaluate whether infant immune responses are associated with the breadth and potency
of maternal immunologic responses to ZIKV over time. To do so we will measure neutralizing antibody activity
in 100 mother-infant pairs over 3 years and explore potential associations with annual infant
neurodevelopmental assessments and timing of infection in gestation. We will also investigate genetic viral
evolution in their ZIKV isolates and are presently sequencing whole ZIKV genome from mother-infant pairs
from the same cohort who had adverse pregnancy outcomes, normal pregnancy outcomes, recurrent or
relapsing infections, while also checking whether there is variability in viral sequences by compartment (CSF,
blood, urine, placenta). We are also evaluating specific ZIKV-immune responses at the cellular and molecular
levels and determining mechanisms by which the virus evades host immune responses during pregnancy. Our
findings will answer important questions pertaining to the mechanisms of immune pathogenesis and intrinsic
virologic factors associated with ZIKV mother-to-child transmission which may be predictive of longer term
infant outcomes. Our well characterized population of mother-infant pairs with detailed clinical follow-up and
specimens collected over time allows us to perform state of the art translational studies to elucidate
mechanisms of viral pathogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10222540
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10174522
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10461773
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
-
批准号:10388193
-
项目类别:
-
资助金额:$75.0万
-
财政年份:2018
-
负责人:GENHONG CHENG
-
依托单位:
IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
-
批准号:8039043
-
项目类别:
-
资助金额:$22.54万
-
财政年份:2011
-
负责人:GENHONG CHENG
-
依托单位:
IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
-
批准号:8208992
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2011
-
负责人:GENHONG CHENG
-
依托单位:
Mitiagrion of Radiation Damage by Mechanisms of Innate Immune Regulation
-
批准号:8011751
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2010
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7741382
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8091282
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8481502
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8282723
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7868050
-
项目类别:
-
资助金额:$37.12万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7687186
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7644341
-
项目类别:
-
资助金额:$28.28万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7388575
-
项目类别:
-
资助金额:$28.28万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:8067083
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7810716
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Viral Mediated Type I Interferon Induction
-
批准号:7587981
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2006
-
负责人:GENHONG CHENG
-
依托单位:
Viral Mediated Type I Interferon Induction
-
批准号:8636981
-
项目类别:
-
资助金额:$37.84万
-
财政年份:2006
-
负责人:GENHONG CHENG
-
依托单位:
Viral Mediated Type I Interferon Induction
-
批准号:9458084
-
项目类别:
-
资助金额:$68.78万
-
财政年份:2006
-
负责人:GENHONG CHENG
-
依托单位:
海外基金